,news_time,news_title,news_link,news_tag
0,2022-11-18,Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted,Vaccines
1,2022-11-11,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-12,Financial
2,2022-11-10,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-1,Vaccines
3,2022-11-04,Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron,COVID-19
4,2022-11-01,PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-strong-third-quarter-2022-results-and-raises,Financial
5,2022-11-01,Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global,Vaccines
6,2022-10-13,Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-early-data-clinical,Vaccines
7,2022-10-12,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-1,Vaccines
8,2022-10-05,Pfizer Completes Acquisition of Global Blood Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics,Financial
9,2022-10-04,Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-talapro-2,Research and Pipeline
10,2022-10-03,Pfizer Completes Acquisition of Biohaven Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals,Financial
11,2022-09-26,Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-0,Vaccines
12,2022-09-22,Pfizer Declares Fourth-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2022-dividend,Financial
13,2022-09-22,Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-global-fund-6-million-paxlovidtm-treatment,Prescription Medicines
14,2022-09-20,Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-1,Financial
15,2022-09-19,Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-0,Research and Pipeline
16,2022-09-15,Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial-0,Vaccines
17,2022-09-14,Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-analyst-and,Financial
18,2022-09-14,Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine,Research and Pipeline
19,2022-09-12,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0,Vaccines
20,2022-09-09,FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata,https://www.pfizer.com//news/press-release/press-release-detail/fda-and-ema-accept-regulatory-submission-pfizers,Prescription Medicines
21,2022-09-07,FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women,https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b,Vaccines
22,2022-09-06,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-11,Financial
23,2022-09-06,Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-10,Financial
24,2022-09-01,Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-two-webcasts-pfizer,Financial
25,2022-09-01,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron,Vaccines
26,2022-08-31,Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization,Vaccines
27,2022-08-26,Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines,Vaccines
28,2022-08-25,Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-trial-older,Vaccines
29,2022-08-23,Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data,Vaccines
30,2022-08-22,Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-use,Vaccines
31,2022-08-19,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-9,Financial
32,2022-08-12,Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20,Vaccines
33,2022-08-08,Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease,Research and Pipeline
34,2022-08-08,Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance,Financial
35,2022-08-05,"Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis",https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-us-fda-approval,Prescription Medicines
36,2022-07-28,PFIZER REPORTS SECOND-QUARTER 2022 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2022-results,Financial
37,2022-06-30,Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda,Prescription Medicines
38,2022-06-29,Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-new-agreement-us-government,Vaccines
39,2022-06-28,Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus,https://www.pfizer.com//news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing,Financial
40,2022-06-25,Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19,Vaccines
41,2022-06-24,Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28-0,Financial
42,2022-06-23,Valneva and Pfizer Announce Closing of Equity Investment,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-closing-equity-investment,Financial
43,2022-06-23,Pfizer Declares Third-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2022-dividend,Financial
44,2022-06-20,Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-enter-equity-subscription-agreement-and,Vaccines
45,2022-06-17,Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use,Vaccines
46,2022-06-17,Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-lancet,Research and Pipeline
47,2022-06-14,Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting,Prescription Medicines
48,2022-06-09,Pfizer Completes Acquisition of ReViral,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-reviral,Financial
49,2022-06-09,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-8,Finance
50,2022-06-08,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-7,Finance
51,2022-06-06,Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invest-120-million-produce-covid-19-oral-treatment,Financial
52,2022-06-04,"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-overall-survival-results-phase-3-paloma-2,Prescription Medicines
53,2022-06-02,Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance-1,Medicines
54,2022-06-01,Pfizer Provides Update on Ownership Interest in Haleon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-ownership-interest-haleon,Investments
55,2022-05-31,Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-6,Finance
56,2022-05-25,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-5,Finance
57,2022-05-25,Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-launches-accord-healthier-world-improve-health,Responsibility
58,2022-05-23,"Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune,Vaccines
59,2022-05-17,Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-us-emergency-use-authorization,Vaccines
60,2022-05-13,Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-covid-19-vaccine-supply,Vaccines
61,2022-05-10,Pfizer to Acquire Biohaven Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-biohaven-pharmaceuticals,Investments
62,2022-05-06,Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-0,Medicines
63,2022-05-03,Pfizer Reports First-Quarter 2022 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-first-quarter-2022-results,Finance
64,2022-04-28,Pfizer Announces 2022 Shareholder Meeting Preliminary Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-2022-shareholder-meeting-preliminary,Finance
65,2022-04-28,Pfizer Declares Second-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-second-quarter-2022-dividend,Finance
66,2022-04-27,Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever,Medicines
67,2022-04-26,Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-positive-phase-2-pediatric-data,Partnerships
68,2022-04-19,Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2022-annual,Finance
69,2022-04-14,Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune,COVID-19
70,2022-04-12,Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-new,Medicines
71,2022-04-11,Pfizer Names David M. Denton Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-names-david-m-denton-chief-financial-officer,Leadership
72,2022-04-07,Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus,Investments
73,2022-03-29,Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-emergency-use,COVID-19
74,2022-03-29,"Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-yearlong-phase-3,Medicines
75,2022-03-24,Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation-0,Vaccines
76,2022-03-23,Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial,Medicines
77,2022-03-22,Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-unicef-4-million-treatment-courses-novel,COVID-19
78,2022-03-11,Pfizer Completes Acquisition of Arena Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals,Financial
79,2022-03-09,Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-23-study-novel-covid-19-oral,Vaccines
80,2022-03-08,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-4,Finance
81,2022-02-28,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-3,Finance
82,2022-02-22,Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-2,Finance
83,2022-02-14,Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results,Research
84,2022-02-11,Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission,COVID-19
85,2022-02-09,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-11,Finance
86,2022-02-08,Pfizer Reports Fourth-Quarter and Full-Year 2021 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2021-results,Finance
87,2022-02-04,Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-data,Research
88,2022-02-01,Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency,COVID-19
89,2022-02-01,Pfizer Announces New Chief Development Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-chief-development-officer,Leadership
90,2022-02-01,Pfizer Invites Public to View and Listen to a Webcast with Pfizer Director Joseph Echevarria to Discuss Board Oversight of ESG,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-0,Responsibility
91,2022-01-31,Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ionis-announce-discontinuation-vupanorsen,Partnerships
92,2022-01-28,European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first,Medicines
93,2022-01-27,Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-chmp-positive-opinion-novel-covid-19-oral,COVID-19
94,2022-01-25,Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based,COVID-19
95,2022-01-24,Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-publish-data-two-laboratory-studies,COVID-19
96,2022-01-21,Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-provide-update-biologics-license,Medicines
97,2022-01-18,Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment,COVID-19
98,2022-01-14,U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults,Medicines
99,2022-01-12,Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring-0,COVID-19
100,2022-01-10,Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-enters-agreement-acuitas-therapeutics-lipid,Research
101,2022-01-10,Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research,Partnerships
102,2022-01-05,Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-complete-collaboration-transaction,Partnerships
103,2022-01-05,Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-sign-new-global-collaboration-agreement,Partnerships
104,2022-01-04,Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-us-government-additional-10-million,COVID-19
105,2022-01-04,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-10,Finance
106,2022-01-03,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-0,COVID-19
107,2021-12-30,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-9,Finance
108,2021-12-28,Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-8,Finance
109,2021-12-22,Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel,COVID-19
110,2021-12-22,Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-united-kingdom-additional-25-million,COVID-19
111,2021-12-20,"Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate",https://www.pfizer.com//news/press-release/press-release-detail/pfizers-vyndaqelrvyndamaxr-reduced-risk-all-cause-mortality,Medicines
112,2021-12-17,"EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency",https://www.pfizer.com//news/press-release/press-release-detail/ema-adopts-positive-chmp-opinion-pfizers-and-opkos,Medicines
113,2021-12-17,CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults,https://www.pfizer.com//news/press-release/press-release-detail/chmp-issues-positive-opinion-pfizers-20-valent-pneumococcal,Vaccines
114,2021-12-17,Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) as First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-lorviquar-lorlatinib,Medicines
115,2021-12-16,EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com//news/press-release/press-release-detail/ema-issues-advice-potential-early-use-pfizers-novel-covid,COVID-19
116,2021-12-15,"Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-685-million-new-state-art-facility-durham,Research
117,2021-12-14,U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0,Medicines
118,2021-12-14,Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results,COVID-19
119,2021-12-13,Pfizer to Acquire Arena Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-arena-pharmaceuticals,Finance
120,2021-12-12,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-1,Research
121,2021-12-10,Pfizer Declares First-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-first-quarter-2022-dividend,Finance
122,2021-12-10,European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqor-abrocitinib,Medicines
123,2021-12-10,Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv,Research
124,2021-12-09,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use,COVID-19
125,2021-12-08,Pfizer and BioNTech Provide Update on Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant,Vaccines
126,2021-12-07,Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-0,COVID-19
127,2021-12-02,AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing,https://www.pfizer.com//news/press-release/press-release-detail/aws-helps-pfizer-accelerate-drug-development-and-clinical,Research
128,2021-11-25,Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion,COVID-19
129,2021-11-24,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer,Finance
130,2021-11-24,Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-topline-results-phase-2b-trial-vupanorsen,Research
131,2021-11-22,Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine,COVID-19
132,2021-11-19,Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation,Research
133,2021-11-19,Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-fda-emergency-use,COVID-19
134,2021-11-18,Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xeljanzr-tofacitinib-receives-marketing,Medicines
135,2021-11-18,Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-us-government-10-million-treatment-courses,Vaccines
136,2021-11-17,Pfizer Completes Acquisition of Trillium Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics,Finance
137,2021-11-17,Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-retirement-chief-financial-officer-frank,Leadership
138,2021-11-16,Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19,COVID-19
139,2021-11-16,Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-medicines-patent-pool-mpp-sign-licensing,Medicines
140,2021-11-11,"Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana",https://www.pfizer.com//news/press-release/press-release-detail/zipline-pfizer-and-biontech-collaboration-paves-way,Partnerships
141,2021-11-10,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-8,Finance
142,2021-11-09,Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-request-amend-us-fda-emergency,COVID-19
143,2021-11-09,Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-enter-strategic-collaboration,Partnerships
144,2021-11-05,Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate,Research
145,2021-11-02,PFIZER REPORTS THIRD-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-third-quarter-2021-results,Finance
146,2021-10-29,Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-fda-emergency-use,Vaccines
147,2021-10-28,Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-50,Vaccines
148,2021-10-26,FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years,https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-favor-granting-emergency-use,Vaccines
149,2021-10-21,Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing,Research
150,2021-10-20,Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults,https://www.pfizer.com//news/press-release/press-release-detail/advisory-committee-immunization-practices-votes-recommend,Vaccines
151,2021-10-19,Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-present-data-relugolix,Research
152,2021-10-18,New Formulation of COMIRNATY® Receives Positive Opinion from CHMP,https://www.pfizer.com//news/press-release/press-release-detail/new-formulation-comirnatyr-receives-positive-opinion-chmp,Vaccines
153,2021-10-15,Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-data-ema-vaccination-children-5,Vaccines
154,2021-10-15,Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-abrocitinib-receives-positive-chmp-opinion,Medicines
155,2021-09-30,Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults,Medicines
156,2021-09-29,Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring,Research
157,2021-09-28,"Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate",https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-results,Research
158,2021-09-28,Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal,COVID-19
159,2021-09-27,Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-starts-study-mrna-based-next-generation-flu-vaccine,Research
160,2021-09-27,Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19,COVID-19
161,2021-09-24,Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-announce-extension-us-fda-review-biologics,Medicines
162,2021-09-23,Pfizer Declares Fourth-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2021-dividend,Finance
163,2021-09-22,Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500,COVID-19
164,2021-09-20,Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results,COVID-19
165,2021-09-17,FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations,https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-unanimously-favor-comirnatyr,COVID-19
166,2021-09-17,Astellas’ and Pfizer’s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study,https://www.pfizer.com//news/press-release/press-release-detail/astellas-and-pfizers-xtandir-enzalutamide-reduced-risk,Research
167,2021-09-09,Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance,Medicines
168,2021-09-09,UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/uks-mhra-grants-marketing-authorisation-pfizers-cibinqor,Medicines
169,2021-09-07,Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer-0,Finance
170,2021-09-02,Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-start-phase-3-clinical-trial-adults-its,Research
171,2021-08-30,Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-jade-dare-trial,Medicines
172,2021-08-26,Pfizer Announces New Chief Business Innovation Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-chief-business-innovation-officer,Finance
173,2021-08-26,Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-brazils,COVID-19
174,2021-08-25,Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission,COVID-19
175,2021-08-23,Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full,Vaccines
176,2021-08-23,Pfizer to Acquire Trillium Therapeutics Inc.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc,Finance
177,2021-08-20,XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanzr-tofacitinib-citrate-receives-marketing,Medicines
178,2021-08-16,Pfizer Prices $1.0 Billion Sustainability Bond,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-prices-10-billion-sustainability-bond,Finance
179,2021-08-16,Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-submission-initial-data-us-fda,COVID-19
180,2021-08-13,"U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis,Vaccines
181,2021-08-12,VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease,https://www.pfizer.com//news/press-release/press-release-detail/vtx-801-receives-us-fda-fast-track-designation-treatment,Vaccines
182,2021-08-04,Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-2b3-trial,Medicines
183,2021-07-28,PFIZER REPORTS SECOND-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2021-results,Finance
184,2021-07-23,Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-200,COVID-19
185,2021-07-22,Arvinas And Pfizer Announce Global Collaboration To Develop And Commercialize Protac® Protein Degrader Arv-471,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop-1,Partnerships
186,2021-07-22,Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop,Medicines
187,2021-07-21,Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-us-fda-review-abrocitinib-and,Medicines
188,2021-07-21,Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-biovac,Partnerships
189,2021-07-19,Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-complete-recruitment-phase-2-trial-lyme,Research
190,2021-07-19,Pfizer Announces New Investor Relations Leader,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-investor-relations-leader,Finance
191,2021-07-08,"Collaboration Between Abbvie, Biogen And Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants To Human Health And Disease.",https://www.pfizer.com//news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-1,Partnerships
192,2021-07-08,"Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease",https://www.pfizer.com//news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-0,Partnerships
193,2021-06-30,Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206,https://www.pfizer.com//news/press-release/press-release-detail/spero-therapeutics-announces-40-million-equity-investment,Partnerships
194,2021-06-24,Pfizer Declares Third-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2021-dividend,Finance
195,2021-06-23,First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC),https://www.pfizer.com//news/press-release/press-release-detail/first-participant-dosed-pfizers-pivotal-phase-3-talapro-3,Medicines
196,2021-06-16,Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia,https://www.pfizer.com//news/press-release/press-release-detail/data-published-new-england-journal-medicine-shows-pfizers,Research
197,2021-06-16,Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-july,Finance
198,2021-06-10,Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-500-million-doses-covid-19,COVID-19
199,2021-06-08,"U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent,Vaccines
200,2021-05-28,Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european,COVID-19
201,2021-05-26,"Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids",https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-fda-approval-myfembreer,Medicines
202,2021-05-24,Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-study-exploring-coadministration-its-20,Research
203,2021-05-20,Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-18-billion,COVID-19
204,2021-05-10,Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-authorization,COVID-19
205,2021-05-07,Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-biologics,COVID-19
206,2021-05-06,Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-covid-19-vaccine-doses-olympic,COVID-19
207,2021-05-04,PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-strong-first-quarter-2021-results,Finance
208,2021-04-28,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-7,Finance
209,2021-04-28,Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals-0,Partnerships
210,2021-04-28,Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals,Finance
211,2021-04-22,Pfizer Declares Second-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-second-quarter-2021-dividend,Finance
212,2021-04-19,Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million-0,COVID-19
213,2021-04-15,Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2021-annual,Finance
214,2021-04-12,Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-first-participant,Research
215,2021-04-07,Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-extension-review-new-drug-application,Medicines
216,2021-04-02,"Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-investor,Finance
217,2021-04-01,Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious,COVID-19
218,2021-03-31,Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal,Research
219,2021-03-26,"EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union",https://www.pfizer.com//news/press-release/press-release-detail/ema-approves-new-storage-option-pfizer-biontech-vaccine,Vaccines
220,2021-03-25,Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain,https://www.pfizer.com//news/press-release/press-release-detail/joint-fda-advisory-committee-votes-application-tanezumab,Medicines
221,2021-03-25,Results from Pfizer’s Phase 3 Jade Compare Study of Abrocitinib in Moderate to Severe Atopic Dermatitis Published in New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/results-pfizers-phase-3-jade-compare-study-abrocitinib,Research
222,2021-03-25,"Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-supports-effectiveness-first-line,Research
223,2021-03-24,Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-data-phase-3,Research
224,2021-03-23,Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral,COVID-19
225,2021-03-23,Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-may-4,Finance
226,2021-03-11,Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared,https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer,COVID-19
227,2021-03-08,Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-initiation-phase-2-study-lyme,Research
228,2021-03-04,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-6,Finance
229,2021-03-03,U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-expands-approval-pfizers-lorbrenar-first-line,Medicines
230,2021-02-26,European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-accepts-pfizers-marketing,Vaccines
231,2021-02-26,EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/ema-accepts-marketing-application-somatrogon-treat,Medicines
232,2021-02-25,Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development,COVID-19
233,2021-02-23,U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine),https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-pfizers-application,Vaccines
234,2021-02-22,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-5,Finance
235,2021-02-19,Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data,COVID-19
236,2021-02-18,Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate,Research
237,2021-02-17,Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-new,Research
238,2021-02-17,Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-pivotal-phase-2-magnetismm-3-trial-bcma,Research
239,2021-02-17,Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-200-million,Vaccines
240,2021-02-12,U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-panzygar-treatment-adults-chronic,Vaccines
241,2021-02-12,Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-united-states-100-million,Vaccines
242,2021-02-09,Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ida-foundation-partner-expand-access-essential,Responsibility
243,2021-02-05,Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer,Medicines
244,2021-02-02,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2020-results,Finance
245,2021-01-27,Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing,Medicines
246,2021-01-26,Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-one-year-data,Research
247,2021-01-25,European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line,Medicines
248,2021-01-22,Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-covax-advance-purchase,COVID-19
249,2021-01-14,Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xalkorir-crizotinib-approved-fda-alk-positive,Medicines
250,2021-01-12,Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-120-million-biotechnology-innovation-through,Partnerships
251,2021-01-10,Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and  Development ofmRNA-based Vaccines and Biotherapies,https://www.pfizer.com//news/press-release/press-release-detail/codex-dna-signs-early-access-collaboration-and-licensing,Partnerships
252,2021-01-07,Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-duchenne,Research
253,2021-01-05,Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer,Finance
254,2021-01-04,US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-regulatory-submission-pfizer-and-opko-review,Research
255,2020-12-29,Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million,COVID-19
256,2020-12-28,LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-snda-previously-untreated-alk-positive,Medicines
257,2020-12-28,Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop,Medicines
258,2020-12-23,Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses,COVID-19
259,2020-12-22,Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-2,Finance
260,2020-12-21,Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union,COVID-19
261,2020-12-21,Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-chmp-positive-opinion-their,COVID-19
262,2020-12-14,Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study,COVID-19
263,2020-12-12,U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/us-cdc-committee-independent-health-experts-recommends,COVID-19
264,2020-12-11,Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization,Vaccines
265,2020-12-11,BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first-0,Medicines
266,2020-12-11,BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first,Medicines
267,2020-12-11,Pfizer Declares First-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-first-quarter-2021-dividend,Finance
268,2020-12-10,Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-fda-advisory-committee-vote,COVID-19
269,2020-12-10,Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark,Research
270,2020-12-08,U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-biologics-license,Vaccines
271,2020-12-07,Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-positive-clinical-data-bcma-cd3-bispecific,Research
272,2020-12-07,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-0,Research
273,2020-12-02,Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world,COVID-19
274,2020-11-23,"Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-evaluating,Research
275,2020-11-20,Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization,COVID-19
276,2020-11-19,Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-lianbio-announce-strategic-collaboration-expand,Partnerships
277,2020-11-19,Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/results-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib,Research
278,2020-11-18,"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine,COVID-19
279,2020-11-16,Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business,Finance
280,2020-11-12,Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg,https://www.pfizer.com//news/press-release/press-release-detail/analysis-phase-3-attr-act-and-its-long-term-extension-study,Medicines
281,2020-11-11,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-4,Finance
282,2020-11-11,"Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-results-fifth-phase-3-trial,Research
283,2020-11-11,Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-supply-eu-200-million,COVID-19
284,2020-11-09,Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/homology-medicines-announces-60-million-equity-investment,Partnerships
285,2020-11-09,Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against,Research
286,2020-11-06,Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-study-results-xeljanz-r,Medicines
287,2020-11-05,Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-details-when-issued-and-ex-distribution,Finance
288,2020-10-30,Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-receive-clearance-us-federal-trade,Finance
289,2020-10-27,"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory,Research
290,2020-10-27,PFIZER REPORTS THIRD-QUARTER 2020 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-third-quarter-2020-results,Finance
291,2020-10-21,Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020,https://www.pfizer.com//news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20,Research
292,2020-10-09,PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint,https://www.pfizer.com//news/press-release/press-release-detail/penelope-b-trial-ibrancer-palbociclib-early-breast-cancer,Medicines
293,2020-10-08,Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-top-line-results-once,Research
294,2020-10-07,Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-dose-first-participant-phase-3-study,Research
295,2020-10-06,BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2,https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-initiate-rolling-submission-european,COVID-19
296,2020-10-05,SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to  Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed  or Refractory Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/springworks-therapeutics-announces-clinical-collaboration,Partnerships
297,2020-10-01,Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne,Research
298,2020-09-28,U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment,Medicines
299,2020-09-24,Pfizer Declares Fourth-Quarter 2020 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2020-dividend,Finance
300,2020-09-23,Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s  Investigational Gene Therapy for Wilson Disease,https://www.pfizer.com//news/press-release/press-release-detail/vivet-therapeutics-and-pfizer-inc-enter-manufacturing,Partnerships
301,2020-09-23,FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma,https://www.pfizer.com//news/press-release/press-release-detail/fda-accepts-supplemental-new-drug-application-pfizers,Medicines
302,2020-09-22,Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-27,Finance
303,2020-09-22,Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive  Pharmacokinetics Platform in Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/javelin-biotech-aims-develop-industry-leading-organ-chip,Partnerships
304,2020-09-18,BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/bavencio-pivotal-phase-iii-javelin-bladder-100-results,Research
305,2020-09-15,Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline,COVID-19
306,2020-09-14,Pfizer Hosts Virtual Investor Day,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-investor-day,Finance
307,2020-09-12,Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19,COVID-19
308,2020-09-11,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-3,Finance
309,2020-09-10,Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-present-latest-scientific-advancements-its-industry,Research
310,2020-09-09,Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna,COVID-19
311,2020-09-09,Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-potentially-supply-eu-200-million-doses,COVID-19
312,2020-09-08,Biopharma Leaders Unite To Stand With Science,https://www.pfizer.com//news/press-release/press-release-detail/biopharma-leaders-unite-stand-science,Vaccines
313,2020-09-03,"Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-virtual-investor-day,Finance
314,2020-08-20,Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna,COVID-19
315,2020-08-07,Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir,COVID-19
316,2020-08-06,"Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-times-rescheduled-virtual-investor-day,Finance
317,2020-08-05,LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-progression,Medicines
318,2020-08-05,Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-canada-their-bnt162-mrna-based,Vaccines
319,2020-07-31,Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-japan-120-million-doses-their,COVID-19
320,2020-07-28,Pfizer Reports Second-Quarter 2020 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2020-results,Finance
321,2020-07-27,Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate,Research
322,2020-07-22,Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600,Vaccines
323,2020-07-20,"Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-update-german,Research
324,2020-07-20,Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-united-kingdom-30,Vaccines
325,2020-07-13,Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two,Vaccines
326,2020-07-09,Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-pledges-100-million-new-industry-fund-help-fight,Finance
327,2020-07-01,Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing,Research
328,2020-06-30,FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-bavencio-first-line-maintenance-treatment,Medicines
329,2020-06-30,European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML),https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-daurismotm-glasdegib-certain,Medicines
330,2020-06-25,Pfizer Declares Third-Quarter 2020 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2020-dividend,Finance
331,2020-06-24,Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-wellcome-launch-surveillance-program-combat,Responsibility
332,2020-06-22,European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior,Medicines
333,2020-06-22,Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-start-four-phase-3-clinical-trials,Research
334,2020-06-22,European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior-0,Research
335,2020-06-18,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results,Research
336,2020-06-18,Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/upjohn-announces-pricing-senior-notes-connection-proposed,Finance
337,2020-06-16,Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28,Finance
338,2020-06-12,Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-june-18,Finance
339,2020-06-11,"FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)",https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-pfizers-oncology-supportive-care-biosimilar,Medicines
340,2020-06-10,Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-jade-teen-trial,Research
341,2020-06-03,Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology,https://www.pfizer.com//news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study,Research
342,2020-06-02,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-2,Finance
343,2020-05-29,"Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-phase-3-pallas-trial-ibrancer,Medicines
344,2020-05-29,Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/final-prosper-results-show-xtandir-enzalutamide,Medicines
345,2020-05-22,"Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-inc-recommends-rejection-unsolicited-note-tender,Finance
346,2020-05-18,"Pfizer Prices $4,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-prices-4000000000-debt-offering,Finance
347,2020-05-15,Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys,Research
348,2020-05-14,Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-lot,Research
349,2020-05-13,"Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day",https://www.pfizer.com//news/press-release/press-release-detail/save-date-pfizer-announces-new-date-september-14-2020,Finance
350,2020-05-12,New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program,https://www.pfizer.com//news/press-release/press-release-detail/new-data-18-approved-and-investigational-pfizer-medicines,Research
351,2020-05-12,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-1,Finance
352,2020-05-08,Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-15,Research
353,2020-05-05,Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program,Research
354,2020-05-04,New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized,https://www.pfizer.com//news/press-release/press-release-detail/new-data-suggest-burden-group-b-streptococcus-gbs-infection,Research
355,2020-04-30,"Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15",https://www.pfizer.com//news/press-release/press-release-detail/valneva_and_pfizer_announce_collaboration_to_co_develop_and_commercialize_lyme_disease_vaccine_vla15,Partnerships
356,2020-04-30,AMRA Medical renews collaboration with Pfizer Inc.  aiming to generate the world’s  largest imaging dataset on body  composition profiling,https://www.pfizer.com//news/press-release/press-release-detail/amra-medical-renews-collaboration-pfizer-inc-aiming,Partnerships
357,2020-04-29,BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany,https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort,Research
358,2020-04-28,PFIZER REPORTS FIRST-QUARTER 2020 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results,Finance
359,2020-04-23,Pfizer Hosts Virtual-Only Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-only-annual-meeting-shareholders,Finance
360,2020-04-22,FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline  of Drugs Targeting DNA Replication Stress for Cancer,https://www.pfizer.com//news/press-release/press-release-detail/forx-therapeutics-ag-raises-eur-10-million-seed-round,Partnerships
361,2020-04-22,BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates,https://www.pfizer.com//news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates,Research
362,2020-04-20,Valneva Receives FDA Fast Track Designation for its Lyme Disease  Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/valneva-receives-fda-fast-track-designation-its-lyme,Partnerships
363,2020-04-09,Pfizer Advances Battle Against COVID-19 on Multiple Fronts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-advances-battle-against-covid-19-multiple-fronts,COVID-19
364,2020-04-09,Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration,COVID-19
365,2020-04-08,U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-braftovir-encorafenib-combination-cetuximab,Medicines
366,2020-04-07,Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hold-virtual-only-2020-annual-meeting-shareholders,Finance
367,2020-04-06,"Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-pfizer-foundation-donate-40-million-charitable,Responsibility
368,2020-04-02,"Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-european-approval-oncology-biosimilar,Medicines
369,2020-04-02,Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/susan-desmond-hellmann-elected-pfizers-board-directors,Leadership
370,2020-04-01,"Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",https://www.pfizer.com//news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and,COVID-19
371,2020-03-27,Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-125-billion-sustainability-bond-social-and,Responsibility
372,2020-03-26,Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-provide-update-regarding-proposed,Finance
373,2020-03-24,"U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-supplemental-new-drug-application-snda,Medicines
374,2020-03-18,Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-top-line-results-phase-3-study-20-valent,Research
375,2020-03-18,"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-third-phase-3,Research
376,2020-03-18,"Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_postpones_investor_day_scheduled_for_march_31_2020_due_to_coronavirus_concerns,Finance
377,2020-03-18,"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_third_phase_3_trial_of_abrocitinib_for_moderate_to_severe_atopic_dermatitis_which_showed_improvements_in_skin_clearance_disease_extent_and_severity_and_itch,Research
378,2020-03-17,Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-april-28,Finance
379,2020-03-17,Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine-0,COVID-19
380,2020-03-17,Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine,COVID-19
381,2020-03-13,Pfizer Outlines Five-Point Plan to Battle COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-outlines-five-point-plan-battle-covid-19,COVID-19
382,2020-03-13,EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study,https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_head_and_neck_100_study,Research
383,2020-03-04,Susan Hockfield Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/susan-hockfield-elected-pfizers-board-directors,Leadership
384,2020-03-02,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_regulatory_submission_for_tanezumab_a_potential_first_in_class_treatment_for_patients_with_chronic_pain_due_to_moderate_to_severe_osteoarthritis,Medicines
385,2020-02-27,James Quincey Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/james-quincey-elected-pfizers-board-directors,Leadership
386,2020-02-27,Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-announce-appointment-viatris-chief,Finance
387,2020-02-27,Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-finalize-appointments-viatris-board,Finance
388,2020-02-27,Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_announce_appointment_of_viatris_chief_financial_officer,Finance
389,2020-02-27,Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_finalize_appointments_to_viatris_board_of_directors,Finance
390,2020-02-25,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_pfizer_discussion_at_healthcare_conference-26,Finance
391,2020-02-20,"Montis Biosciences launched with €8,4 million seed financing and a novel  approach to immune-oncology",https://www.pfizer.com//news/press-release/press-release-detail/montis-biosciences-launched-eu84-million-seed-financing-and,Partnerships
392,2020-02-18,"European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-vyndaqelr-first-treatment-eu,Medicines
393,2020-02-11,XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC,https://www.pfizer.com//news/press-release/press-release-detail/xtandir-enzalutamide-demonstrates-significant-improvement,Research
394,2020-01-31,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-oncology-biosimilar,Medicines
395,2020-01-28,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2019-results,Finance
396,2020-01-23,Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-vaccines-launches-global-centers-excellence-network,Vaccines
397,2020-01-23,Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate),https://www.pfizer.com//news/press-release/press-release-detail/pfizers-greenstone-and-digital-mens-health-clinic-roman,Medicines
398,2020-01-14,Insilico enters into research collaboration with Pfizer Inc. to explore novel data  and artificial intelligence system for potential therapeutic targets,https://www.pfizer.com//news/press-release/press-release-detail/insilico-enters-research-collaboration-pfizer-inc-explore,Partnerships
399,2020-01-13,Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease  and Parkinson’s Disease from Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/biogen-acquire-novel-clinical-stage-asset-application,Partnerships
400,2020-01-13,Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine  Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate,https://www.pfizer.com//news/press-release/press-release-detail/axsome-therapeutics-enters-exclusive-license-agreement,Partnerships
401,2020-01-07,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-0,Finance
402,2020-01-06,BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencio-significantly-improved-overall-survival-patients,Research
403,2019-12-23,"Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program",https://www.pfizer.com//news/press-release/press-release-detail/theravance_biopharma_and_pfizer_inc_enter_global_license_agreement_for_skin_targeted_locally_acting_pan_janus_kinase_jak_inhibitor_program,Partnerships
404,2019-12-23,BioInvent announces selection of second target and extension of the research  collaboration and license agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/bioinvent-announces-selection-second-target-and-extension,Partnerships
405,2019-12-18,U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_and_grants_priority_review_to_snda_for_braftovi_encorafenib_in_combination_with_erbitux_cetuximab_braftovi_doublet_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_after_prior,Medicines
406,2019-12-18,Pfizer and Mylan Announce Two Future Viatris Board Members,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_mylan_announce_two_future_viatris_board_members,Finance
407,2019-12-17,Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_january_28_conference_call_with_analysts-0,Finance
408,2019-12-17,Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of  Transformative Treatments for Triplet Repeat Disorders,https://www.pfizer.com//news/press-release/press-release-detail/triplet-therapeutics-launches-59-million-financing-further,Partnerships
409,2019-12-16,XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/xtandi_enzalutamide_approved_by_u_s_fda_for_the_treatment_of_metastatic_castration_sensitive_prostate_cancer,Medicines
410,2019-12-16,Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2020_dividend_and_announces_upcoming_investor_day_to_highlight_strength_of_innovative_r_d_pipeline,Finance
411,2019-12-13,"Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vyndaqel_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease,Medicines
412,2019-12-12,FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_xeljanz_xr_tofacitinib_extended_release_tablets_for_the_treatment_of_ulcerative_colitis,Medicines
413,2019-12-10,"ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and  BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials",https://www.pfizer.com//news/press-release/press-release-detail/immunos-therapeutics-ag-raises-chf-15m-series-financing-co,Partnerships
414,2019-12-07,Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer,https://www.pfizer.com//news/press-release/press-release-detail/findings_released_from_real_world_data_analysis_of_eliquis_apixaban_for_the_treatment_of_venous_thromboembolism_in_patients_with_active_cancer,Research
415,2019-12-07,Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_showing_sustained_increased_factor_viii_activity_through_44_weeks_following_sb_525_gene_therapy_treatment,Research
416,2019-12-04,ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel  Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases,https://www.pfizer.com//news/press-release/press-release-detail/imcheck-raises-53-million-series-b-advance-clinical,Partnerships
417,2019-11-22,CeMM enters into research collaboration on expanding the druggable proteome  with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/cemm-enters-research-collaboration-expanding-druggable,Partnerships
418,2019-11-18,"FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions",https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions,Medicines
419,2019-11-15,"Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals",https://www.pfizer.com//news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_randomized_controlled_trial_to_evaluate_the_effect_of_atrial_fibrillation_screening_on_health_outcomes_in_older_individuals,Research
420,2019-11-13,CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/centogene-signs-data-access-and-collaboration-agreement,Partnerships
421,2019-11-12,Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_announce_viatris_as_the_new_company_name_in_the_planned_mylan_upjohn_combination,Finance
422,2019-11-12,Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_of_phase_3_study_for_xeljanz_tofacitinib_in_juvenile_idiopathic_arthritis_ahead_of_presentation_at_2019_american_college_of_rheumatology_association_of_rheumatology_professionals_annual,Research
423,2019-11-08,EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial,https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_gastric_100_trial,Research
424,2019-10-29,PFIZER REPORTS THIRD-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_third_quarter_2019_results,Finance
425,2019-10-28,European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_plus_axitinib_combination_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma,Medicines
426,2019-10-21,"OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency",https://www.pfizer.com//news/press-release/press-release-detail/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency,Research
427,2019-10-17,The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis,https://www.pfizer.com//news/press-release/press-release-detail/the_bristol_myers_squibb_pfizer_alliance_and_fitbit_collaborate_to_address_gaps_in_atrial_fibrillation_detection_with_the_aim_of_accelerating_diagnosis,Partnerships
428,2019-10-14,ImaginAb signs multi-party collaboration agreement with three global  pharmaceutical companies to help further develop company’s CD8  ImmunoPET technology,https://www.pfizer.com//news/press-release/press-release-detail/imaginab-signs-multi-party-collaboration-agreement-three,Partnerships
429,2019-10-12,Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_phase_3_data_at_the_28th_congress_of_the_european_academy_of_dermatology_and_venereology_for_abrocitinib_in_moderate_to_severe_atopic_dermatitis,Research
430,2019-10-07,Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx,https://www.pfizer.com//news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx,Partnerships
431,2019-09-29,"Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_interim_analysis_results_from_phase_3_beacon_crc_trial_of_braftovi_encorafenib_mektovi_binimetinib_and_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer,Research
432,2019-09-27,Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman,https://www.pfizer.com//news/press-release/press-release-detail/ian_read_to_retire_as_executive_chairman_of_pfizer_s_board_of_directors_chief_executive_officer_dr_albert_bourla_named_chairman,Leadership
433,2019-09-27,"Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_second_pivotal_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis,Research
434,2019-09-27,New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019,https://www.pfizer.com//news/press-release/press-release-detail/new_data_for_bavencio_avelumab_for_advanced_cancers_to_be_presented_at_esmo_2019,Research
435,2019-09-24,Pfizer Declares Fourth-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_fourth_quarter_2019_dividend,Finance
436,2019-09-24,"Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_new_evidence_of_ibrance_palbociclib_effectiveness_in_hr_her2_metastatic_breast_cancer_patients_in_four_real_world_studies_at_esmo_congress_2019,Medicines
437,2019-09-24,Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_flatiron_health_announce_expanded_strategic_collaboration_to_unlock_power_of_real_world_evidence_in_oncology,Partnerships
438,2019-09-20,CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/chmp_adopts_positive_opinion_for_bavencio_avelumab_plus_axitinib_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma,Medicines
439,2019-09-19,Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_scientific_advancements_in_cancer_care_at_the_esmo_congress_2019_highlighting_expanded_portfolio,Research
440,2019-09-17,Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_october_29_conference_call_with_analysts-0,Finance
441,2019-09-09,Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_preliminary_results_from_a_proof_of_concept_phase_2_study_b7471003_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and,Research
442,2019-08-21,U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_xtandi_enzalutamide_application_priority_review_for_the_treatment_of_men_with_metastatic_hormone_sensitive_prostate_cancer,Medicines
443,2019-08-21,"Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invests_half_billion_dollars_to_advance_state_of_the_art_gene_therapy_facility_in_sanford_north_carolina,Finance
444,2019-08-20,The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance,https://www.pfizer.com//news/press-release/press-release-detail/the_pfizer_foundation_invests_in_20_organizations_tackling_infectious_diseases_and_antimicrobial_resistance,Research
445,2019-08-02,Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis,Research
446,2019-08-01,Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_closing_of_joint_venture_with_glaxosmithkline_to_create_a_premier_global_consumer_healthcare_company,Partnerships
447,2019-07-31,BioInvent announces selection of first target discovered by BioInvent’s  proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/bioinvent-announces-selection-first-target-discovered,Partnerships
448,2019-07-30,Pfizer Completes Acquisition of Array Biopharma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_completes_acquisition_of_array_biopharma,Finance
449,2019-07-29,"Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_inc_reschedules_second_quarter_2019_earnings_conference_call_to_july_29_2019_at_10_30_a_m_edt,Finance
450,2019-07-29,PFIZER REPORTS SECOND-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_second_quarter_2019_results,Finance
451,2019-07-29,"Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine",https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_upjohn_a_division_of_pfizer_to_combine_creating_a_new_champion_for_global_health_uniquely_positioned_to_fulfill_the_world_s_need_for_medicine,Finance
452,2019-07-23,"FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions",https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions,Medicines
453,2019-07-05,Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_for_sb_525_investigational_hemophilia_a_gene_therapy_showing_sustained_increased_factor_viii_levels,Research
454,2019-07-01,Pfizer Completes Acquisition of Therachon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_completes_acquisition_of_therachon,Finance
455,2019-07-01,"Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_4_study_of_crisaborole_ointment_2_in_children_aged_3_months_to_less_than_24_months_with_mild_to_moderate_atopic_dermatitis,Research
456,2019-06-28,Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_from_phase_3_trial_of_revatio_sildenafil_citrate_in_newborns_with_persistent_pulmonary_hypertension,Research
457,2019-06-28,Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD),https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd,Research
458,2019-06-28,"Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr,Medicines
459,2019-06-27,Scott Gottlieb Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/scott_gottlieb_elected_to_pfizer_s_board_of_directors,Leadership
460,2019-06-27,Pfizer Declares Third-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_third_quarter_2019_dividend,Finance
461,2019-06-21,European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer,Medicines
462,2019-06-18,Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_30_conference_call_with_analysts-0,Finance
463,2019-06-17,Pfizer to Acquire Array BioPharma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma,Finance
464,2019-06-12,"Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_from_xeljanz_xr_tofacitinib_oral_shift_study_the_first_phase_3b_4_study_to_evaluate_methotrexate_withdrawal_with_a_jak_inhibitor,Medicines
465,2019-06-05,"Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development",https://www.pfizer.com//news/press-release/press-release-detail/jeff_settleman_ph_d_joins_pfizer_to_lead_oncology_research_development,Leadership
466,2019-05-24,Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_top_line_results_from_phase_3_trial_of_lyrica_pregabalin_in_primary_generalized_tonic_clonic_seizures,Medicines
467,2019-05-15,Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_new_data_from_innovative_science_that_address_patient_needs_at_asco_2019_annual_meeting,Research
468,2019-05-15,"Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis,Research
469,2019-05-14,FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma,Medicines
470,2019-05-09,"Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_opens_new_state_of_the_art_biologics_clinical_manufacturing_facility_in_andover_massachusetts,Finance
471,2019-05-08,Pfizer Acquires Clinical-Stage Biotech Therachon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_acquires_clinical_stage_biotech_therachon,Finance
472,2019-05-07,European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer,Medicines
473,2019-05-06,"U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease,Medicines
474,2019-04-30,PFIZER REPORTS FIRST-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_first_quarter_2019_results,Finance
475,2019-04-26,Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer,Medicines
476,2019-04-25,Pfizer Hosts Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-6,Finance
477,2019-04-18,Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_long_term_phase_3_study_of_tanezumab_in_patients_with_osteoarthritis,Research
478,2019-04-18,Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_25_annual_meeting_of_shareholders-0,Finance
479,2019-04-13,Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_presentation_of_data_from_a_phase_2_study_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years,Research
480,2019-04-04,"U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer,Medicines
481,2019-04-03,VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/vizimpro_dacomitinib_receives_marketing_authorization_in_european_union_eu_for_the_first_line_treatment_of_adult_patients_with_egfr_mutated_non_small_cell_lung_cancer,Medicines
482,2019-04-02,Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy,Research
483,2019-03-20,Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_secures_exclusive_option_to_acquire_gene_therapy_company_vivet_therapeutics,Finance
484,2019-03-19,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_announce_discontinuation_of_phase_iii_javelin_ovarian_parp_100_trial_in_previously_untreated_advanced_ovarian_cancer,Research
485,2019-03-19,Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_april_30_conference_call_with_analysts-0,Finance
486,2019-03-17,AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention,https://www.pfizer.com//news/press-release/press-release-detail/augustus_demonstrates_favorable_safety_results_of_eliquis_versus_vitamin_k_antagonists_in_non_valvular_atrial_fibrillation_patients_with_acute_coronary_syndrome_and_or_undergoing_percutaneous_coronary_intervention,Research
487,2019-03-11,"U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_oncology_biosimilar_trazimera_trastuzumab_qyyp_a_biosimilar_to_herceptin_1,Medicines
488,2019-03-08,European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european_medicines_agency_validates_application_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma,Medicines
489,2019-03-05,Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-23,Finance
490,2019-03-04,"Pfizer Prices $5,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering-0,Finance
491,2019-03-01,Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer,Medicines
492,2019-02-28,Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_serotypes_included_in_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older,Research
493,2019-02-19,Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials,https://www.pfizer.com//news/press-release/press-release-detail/ochsner_health_system_and_pfizer_partner_to_develop_innovative_models_for_clinical_trials,Research
494,2019-02-19,"Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_european_approval_for_zirabev_bevacizumab_a_biosimilar_to_avastin,Medicines
495,2019-02-19,Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_phase_3_study_of_tanezumab_in_chronic_low_back_pain,Research
496,2019-02-16,Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/pivotal_phase_iii_data_for_bavencio_avelumab_plus_inlyta_axitinib_in_advanced_renal_cell_carcinoma_published_in_the_new_england_journal_of_medicine,Research
497,2019-02-12,"G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s  Groton, Conn. Site",https://www.pfizer.com//news/press-release/press-release-detail/g-con-manufacturing-delivers-new-pcmm-podr-tablet-coating,Partnerships
498,2019-02-11,FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda_accepts_sbla_and_grants_priority_review_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma,Medicines
499,2019-02-11,Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/phase_3_arches_trial_shows_xtandi_enzalutamide_significantly_improved_radiographic_progression_free_survival_in_men_with_metastatic_hormone_sensitive_prostate_cancer,Research
500,2019-02-04,The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients,https://www.pfizer.com//news/press-release/press-release-detail/the_union_for_international_cancer_control_and_pfizer_announce_new_phase_of_global_grants_initiative_supporting_metastatic_breast_cancer_patients,Responsibility
501,2019-02-01,Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vizimpro_dacomitinib_for_the_first_line_treatment_of_adult_patients_with_locally_advanced_or_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations,Medicines
502,2019-01-29,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2018_results,Finance
503,2019-01-29,Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_second_phase_3_study_of_tanezumab_in_osteoarthritis_pain,Research
504,2019-01-14,US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/us_fda_accepts_regulatory_submissions_for_review_of_tafamidis_to_treat_transthyretin_amyloid_cardiomyopathy,Medicines
505,2019-01-09,eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types,https://www.pfizer.com//news/press-release/press-release-detail/effector-enters-agreement-pfizer-inc-develop-novel-first-,Partnerships
506,2019-01-07,CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model  of the Immune System for Drug Discovery,https://www.pfizer.com//news/press-release/press-release-detail/cytoreason-signs-collaboration-agreement-pfizer-inc-utilize,Partnerships
507,2019-01-03,"Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_phase_2b_3_clinical_trial_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_alopecia_areata,Research
508,2018-12-21,"Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_javelin_ovarian_100_trial_of_avelumab_in_previously_untreated_advanced_ovarian_cancer,Research
509,2018-12-20,Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis,https://www.pfizer.com//news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis,Research
510,2018-12-20,Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/astellas_and_pfizer_announce_positive_top_line_results_from_phase_3_arches_trial_of_xtandi_enzalutamide_in_men_with_metastatic_hormone_sensitive_prostate_cancer,Research
511,2018-12-18,Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_glaxosmithkline_announce_joint_venture_to_create_a_premier_global_consumer_healthcare_company,Partnerships
512,2018-12-18,Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_january_29_conference_call_with_analysts-0,Finance
513,2018-12-17,Kineta Enters Research Collaboration and License Agreement  with Pfizer to Develop New Cancer Immunotherapies,https://www.pfizer.com//news/press-release/press-release-detail/kineta-enters-research-collaboration-and-license-agreement,Partnerships
514,2018-12-14,Pfizer Declares First-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2019_dividend,Finance
515,2018-12-14,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_zirabev_bevacizumab,Medicines
516,2018-12-14,Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_phase_3_program_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older,Research
517,2018-12-02,"Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_26_week_data_for_pf_05280586_a_potential_biosimilar_to_rituximab_at_the_american_society_of_hematology_annual_meeting,Research
518,2018-11-30,Pfizer Reaches a Global Agreement with AbbVie,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reaches_a_global_agreement_with_abbvie,Partnerships
519,2018-11-27,Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin),https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_six_months_pediatric_exclusivity_for_lyrica_pregabalin,Medicines
520,2018-11-21,U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_daurismo_glasdegib_for_adult_patients_with_newly_diagnosed_acute_myeloid_leukemia_aml_for_whom_intensive_chemotherapy_is_not_an_option,Medicines
521,2018-11-19,"Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_avelumab_in_platinum_resistant_refractory_ovarian_cancer,Research
522,2018-11-02,U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_lorbrena_lorlatinib_for_previously_treated_alk_positive_metastatic_nsclc,Medicines
523,2018-10-30,PFIZER REPORTS THIRD-QUARTER 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_third_quarter_2018_results,Finance
524,2018-10-28,Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_clinical_development_agreement_with_novartis_to_advance_the_treatment_of_nash,Research
525,2018-10-25,CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL  CANCER DRUGS,https://www.pfizer.com//news/press-release/press-release-detail/cancer-therapeutics-crc-signs-agreement-enable-pfizer,Partnerships
526,2018-10-23,Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients,https://www.pfizer.com//news/press-release/press-release-detail/complete_results_from_first_study_in_ongoing_phase_3_program_for_tanezumab_demonstrated_significant_improvement_in_pain_and_function_in_osteoarthritis_patients,Research
527,2018-10-23,"Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company",https://www.pfizer.com//news/press-release/press-release-detail/bain_capital_and_pfizer_create_cerevel_therapeutics_new_cns_company,Partnerships
528,2018-10-20,"Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_overall_survival_data_from_paloma_3_trial_of_ibrance_palbociclib_in_patients_with_hr_her2_metastatic_breast_cancer,Research
529,2018-10-16,U.S. FDA Approves TALZENNA® (talazoparib),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_talzenna_talazoparib,Medicines
530,2018-10-09,Pfizer Announces Executive Leadership Team,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_executive_leadership_team,Leadership
531,2018-10-04,Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_award_more_than_3_million_in_grants_to_further_breast_cancer_research,Finance
532,2018-10-01,Pfizer Announces CEO Succession,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_ceo_succession,Leadership
533,2018-09-27,U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer,Medicines
534,2018-09-27,Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_34_cent_fourth_quarter_2018_dividend,Finance
535,2018-09-20,Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older,Vaccines
536,2018-09-18,Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_october_30_conference_call_with_analysts-0,Finance
537,2018-09-18,New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting,https://www.pfizer.com//news/press-release/press-release-detail/new_sub_group_analyses_from_the_tafamidis_phase_3_transthyretin_amyloid_cardiomyopathy_attr_act_study_presented_at_2018_hfsa_annual_scientific_meeting,Research
538,2018-09-17,ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER,https://www.pfizer.com//news/press-release/press-release-detail/atomwise-enters-evaluation-agreement-pfizer,Partnerships
539,2018-09-14,Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_phase_2_data_in_alopecia_areata_during_late_breaker_session_at_the_27th_european_academy_of_dermatology_and_venereology_eadv_congress,Research
540,2018-09-12,System1 Announces a $25 Million Series A Funding to Advance  Integrated Technology Platform for Neurotherapeutics Discovery,https://www.pfizer.com//news/press-release/press-release-detail/system1-announces-25-million-series-funding-advance,Partnerships
541,2018-09-11,BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study,https://www.pfizer.com//news/press-release/press-release-detail/bavencio_avelumab_plus_inlyta_axitinib_significantly_improved_progression_free_survival_in_previously_untreated_patients_with_advanced_renal_cell_carcinoma_in_phase_iii_study,Research
542,2018-09-06,CYTOO enters into Research and Option Agreement with Pfizer to develop a  target discovery platform for Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/cytoo-enters-research-and-option-agreement-pfizer-develop,Partnerships
543,2018-09-05,4D Molecular Therapeutics Raises $90 Million Series B Financing,https://www.pfizer.com//news/press-release/press-release-detail/4d-molecular-therapeutics-raises-90-million-series-b,Partnerships
544,2018-09-05,"Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata,Medicines
545,2018-09-04,"Pfizer Prices $5,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering,Finance
546,2018-08-30,Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy,Research
547,2018-08-22,Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_astellas_amend_clinical_research_protocols_for_two_phase_3_trials_of_enzalutamide_in_patients_with_hormone_sensitive_prostate_cancer,Research
548,2018-08-20,Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_august_27_conference_call_with_analysts_and_investors_to_review_tafamidis_data_presentation_at_esc_congress_2018,Finance
549,2018-08-16,BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza,https://www.pfizer.com//news/press-release/press-release-detail/biontech-signs-collaboration-agreement-pfizer-develop-mrna,Partnerships
550,2018-08-08,SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2  ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A,https://www.pfizer.com//news/press-release/press-release-detail/sangamo-announces-positive-preliminary-data-phase-12-alta,Partnerships
551,2018-08-01,XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0,Medicines
552,2018-07-31,PFIZER REPORTS SECOND-QUARTER 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_second_quarter_2018_results-0,Finance
553,2018-07-31,"Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_european_approval_for_oncology_biosimilar_trazimera_trastuzumab-0,Medicines
554,2018-07-24,"Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_build_cutting_edge_sterile_injectable_facility_in_michigan_investing_nearly_half_a_billion_dollars_in_u_s_manufacturing_creating_more_than_450_jobs-0,Finance
555,2018-07-20,U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_biosimilar_nivestym_filgrastim_aafi-0,Medicines
556,2018-07-18,Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_positive_top_line_results_from_phase_3_trial_of_tanezumab_for_the_treatment_of_osteoarthritis_oa_pain,Research
557,2018-07-16,Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_pivotal_phase_3_program_for_investigational_hemophilia_b_gene_therapy-0,Research
558,2018-07-13,U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_xtandi_enzalutamide_for_the_treatment_of_men_with_non_metastatic_castration_resistant_prostate_cancer_crpc-0,Medicines
559,2018-07-11,Pfizer to Organize for Future Growth,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_organize_for_future_growth-0,Leadership
560,2018-06-28,XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorisation_in_the_european_union_for_active_psoriatic_arthritis-0,Medicines
561,2018-06-28,Pfizer Declares 34-Cent Third-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_34_cent_third_quarter_2018_dividend-0,Finance
562,2018-06-27,U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_pfizer_s_new_drug_application_for_glasdegib_in_patients_with_previously_untreated_acute_myeloid_leukemia-0,Research
563,2018-06-25,"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_overall_survival_results_from_phase_3_paloma_3_trial_of_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer-0,Medicines
564,2018-06-19,Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_31_conference_call_with_analysts-1,Finance
565,2018-06-12,Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_extension_of_zithromax_antibiotic_donation_program_through_2025_to_help_eliminate_world_s_leading_infectious_cause_of_blindness-0,Responsibility
566,2018-06-07,U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_talazoparib_for_metastatic_breast_cancer_patients_with_an_inherited_brca_mutation-1,Medicines
567,2018-06-04,Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/dacomitinib_shows_more_than_seven_month_improvement_in_overall_survival_compared_to_an_established_therapy_in_advanced_nsclc_with_egfr_activating_mutations-0,Research
568,2018-06-04,Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab),https://www.pfizer.com//news/press-release/press-release-detail/two_year_update_of_pivotal_javelin_merkel_200_trial_shows_continued_durable_responses_with_bavencio_avelumab,Medicines
569,2018-06-01,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_trazimera_trastuzumab-0,Medicines
570,2018-05-31,Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress,https://www.pfizer.com//news/press-release/press-release-detail/cortexyme-completes-76-million-series-b-financing-and,Partnerships
571,2018-05-30,Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_u_s_fda_approves_xeljanz_tofacitinib_for_the_treatment_of_moderately_to_severely_active_ulcerative_colitis-0,Medicines
572,2018-05-30,The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families,https://www.pfizer.com//news/press-release/press-release-detail/the_pfizer_foundation_announces_5_million_in_grants_to_support_women_and_families-0,Responsibility
573,2018-05-29,Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0,Medicines
574,2018-05-23,FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/fda_grants_breakthrough_therapy_designation_for_tafamidis_for_the_treatment_of_patients_with_transthyretin_cardiomyopathy-1,Research
575,2018-05-22,A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+,https://www.pfizer.com//news/press-release/press-release-detail/a_study_analyzing_observational_data_shows_real_world_effectiveness_of_prevnar_13_in_adults_age_65-0,Research
576,2018-05-22,Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_begins_a_phase_1_2_study_to_evaluate_respiratory_syncytial_virus_rsv_vaccine-0,Research
577,2018-05-21,Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events,https://www.pfizer.com//news/press-release/press-release-detail/spark_therapeutics_and_pfizer_announce_data_from_15_participants_with_hemophilia_b_showing_persistent_and_sustained_factor_ix_levels_with_no_serious_adverse_events,Research
578,2018-05-17,LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint,https://www.pfizer.com//news/press-release/press-release-detail/lyrica_pregabalin_oral_solution_cv_phase_3_trial_in_pediatric_epilepsy_meets_primary_endpoint-0,Medicines
579,2018-05-16,Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_clinical_advances_from_its_growing_portfolio_and_research_pipeline_at_asco,Research
580,2018-05-15,Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_biosimilar_retacrit_epoetin_alfa_epbx_approved_by_u_s_fda,Medicines
581,2018-05-08,XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop  Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery,https://www.pfizer.com//news/press-release/press-release-detail/xtalpi-inc-announces-strategic-research-collaboration,Partnerships
582,2018-05-08,New project to enhance nanomedicine development,https://www.pfizer.com//news/press-release/press-release-detail/new-project-enhance-nanomedicine-development,Partnerships
583,2018-05-07,Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer,https://www.pfizer.com//news/press-release/press-release-detail/wave-life-sciences-highlights-progress-hepatic,Partnerships
584,2018-05-01,HUB Announces Collaboration with Pfizer Inc. on Human Gut Organoids for  IBD,https://www.pfizer.com//news/press-release/press-release-detail/hub-announces-collaboration-pfizer-inc-human-gut-organoids,Partnerships
585,2018-05-01,Pfizer Reports First-Quarter 2018 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_first_quarter_2018_results,Finance
586,2018-04-26,Pfizer Hosts Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-5,Finance
587,2018-04-23,Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_trumenba_meningococcal_group_b_vaccine_for_the_prevention_of_invasive_meningococcal_b_disease_in_children_ages_1_to_9_years,Vaccines
588,2018-04-23,Pfizer Provides Update on Proposed Trastuzumab Biosimilar,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_provides_update_on_proposed_trastuzumab_biosimilar,Medicines
589,2018-04-23,"MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy",https://www.pfizer.com//news/press-release/press-release-detail/mylotarg_approved_in_the_eu_for_the_treatment_of_previously_untreated_de_novo_cd33_positive_acute_myeloid_leukemia_in_combination_with_chemotherapy,Medicines
590,2018-04-19,Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_26_annual_meeting_of_shareholders-0,Finance
591,2018-04-12,Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_doses_first_patient_using_investigational_mini_dystrophin_gene_therapy_for_the_treatment_of_duchenne_muscular_dystrophy,Research
592,2018-04-10,Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_provides_update_on_phase_3_trial_of_axitinib_as_adjuvant_treatment_for_patients_at_high_risk_of_renal_cell_carcinoma_recurrence_after_surgery,Research
593,2018-04-10,Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_signs_lease_for_the_spiral_at_hudson_yards_in_manhattan,Finance
594,2018-04-04,U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_dacomitinib_to_treat_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations,Medicines
595,2018-04-03,Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_allogene_therapeutics_enter_into_asset_contribution_agreement_for_pfizer_s_allogeneic_car_t_immuno_oncology_portfolio,Research
596,2018-03-29,Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_topline_results_from_phase_3_attr_act_study_of_tafamidis_in_patients_with_transthyretin_cardiomyopathy,Research
597,2018-03-23,Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_top_line_results_from_a_study_of_chantix_champix_varenicline_in_adolescent_smokers,Research
598,2018-03-19,U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_a_supplemental_new_drug_application_snda_for_xtandi_enzalutamide_in_non_metastatic_castration_resistant_prostate_cancer_crpc,Medicines
599,2018-03-19,BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable  Fluorosulfation Reagent,https://www.pfizer.com//news/press-release/press-release-detail/bioduro-collaboration-pfizer-inc-leads-creation-shelf,Partnerships
600,2018-03-12,BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET  FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA,https://www.pfizer.com//news/press-release/press-release-detail/biogen-acquire-pfizer-first-class-phase-2b-ready-asset,Partnerships
601,2018-03-11,Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants,https://www.pfizer.com//news/press-release/press-release-detail/findings_released_from_largest_real_world_data_analysis_of_non_valvular_atrial_fibrillation_patients_receiving_direct_oral_anticoagulants,Research
602,2018-03-09,AM‐Pharma announces Phase II study results of recAP in sepsis‐associated Acute  Kidney Injury,https://www.pfizer.com//news/press-release/press-release-detail/am-pharma-announces-phase-ii-study-results-recap-sepsis,Partnerships
603,2018-03-08,Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_favorable_outcome_of_fda_advisory_committee_meeting_on_xeljanz_tofacitinib_for_moderately_to_severely_active_ulcerative_colitis,Medicines
604,2018-03-07,Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-22,Finance
605,2018-03-05,Dan R. Littman Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/dan_r_littman_elected_to_pfizer_s_board_of_directors,Leadership
606,2018-03-02,Neofluidics Announces Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/neofluidics-announces-collaboration-pfizer-inc,Partnerships
607,2018-02-28,Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular  disease,https://www.pfizer.com//news/press-release/press-release-detail/inserm-announces-research-agreement-pfizer-inc-study-rare,Partnerships
608,2018-02-23,"Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_two_hematology_medicines_mylotarg_and_bosulif,Medicines
609,2018-02-23,Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_update_on_european_marketing_authorization_application_for_sutent_sunitinib_in_adult_patients_at_high_risk_of_recurrent_renal_cell_carcinoma,Medicines
610,2018-02-23,Albert Bourla Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/albert_bourla_elected_to_pfizer_s_board_of_directors,Leadership
611,2018-02-14,"Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_04965842_an_oral_jak1_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_atopic_dermatitis,Medicines
612,2018-02-12,"U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib",https://www.pfizer.com//news/press-release/press-release-detail/u_s_eu_and_japan_health_authorities_accept_regulatory_submissions_for_review_of_pfizer_s_third_generation_alk_inhibitor_lorlatinib,Research
613,2018-02-05,Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/phase_3_prosper_trial_shows_xtandi_enzalutamide_significantly_reduced_the_risk_of_metastasis_or_death_by_71_percent_in_men_with_non_metastatic_castration_resistant_prostate_cancer,Research
614,2018-01-30,Pfizer Reports Fourth-Quarter and Full-Year 2017 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2017_results,Finance
615,2018-01-24,Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_for_potential_biosimilar_to_rituxan_mabthera,Medicines
616,2018-01-22,MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON SPECIALIZED IMMUNE CELLS WITH PFIZER INC.,https://www.pfizer.com//news/press-release/press-release-detail/mindimmune-therapeutics-conduct-research-specialized-immune,Partnerships
617,2018-01-19,Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients,https://www.pfizer.com//news/press-release/press-release-detail/survey_of_ulcerative_colitis_patients_and_gastroenterologists_indicates_that_symptoms_may_create_a_new_reality_for_patients,Research
618,2018-01-17,Circle Pharma announces publication in Journal of Medicinal Chemistry of results from  collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/circle-pharma-announces-publication-journal-medicinal,Partnerships
619,2018-01-09,Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Products  Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/adapsyn-bioscience-completes-financing-advance-its-small,Partnerships
620,2018-01-08,Imcyse announces a research collaboration with  Pfizer Inc. in rheumatoid arthritis (RA),https://www.pfizer.com//news/press-release/press-release-detail/imcyse-announces-research-collaboration-pfizer-inc,Partnerships
621,2018-01-08,Regeneron Forms Consortium of Leading Life Sciences Companies to  Accelerate Largest Widely-Available ‘Big Data’ Human Sequencing Resource with UK Biobank,https://www.pfizer.com//news/press-release/press-release-detail/regeneron-forms-consortium-leading-life-sciences-companies,Partnerships
622,2018-01-08,"Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel  and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of  Alexandria LaunchLabs",https://www.pfizer.com//news/press-release/press-release-detail/alexandria-venture-investments-launches-alexandria-seed,Partnerships
623,2018-01-08,Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_inc_announces_expiration_and_results_of_its_tender_offer_for_its_5_750_per_cent_notes_due_2021_and_related_solicitation_of_consents,Finance
624,2018-01-08,Pfizer Establishes New Partnering Model for Early-Stage Academic Research,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_establishes_new_partnering_model_for_early_stage_academic_research,Research
625,2018-01-05,Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/distributed-bio-announces-superhuman-platform-license-0,Partnerships
626,2018-01-05,Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/distributed-bio-announces-superhuman-platform-license,Partnerships
627,2018-01-04,Berkeley Lights Announces Research Collaboration and License Agreement with Pfizer,https://www.pfizer.com//news/press-release/press-release-detail/berkeley-lights-announces-research-collaboration-and,Partnerships
628,2018-01-03,Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_collaboration_for_development_of_zinc_finger_protein_gene_therapy_for_als,Partnerships
629,2017-12-18,Pfizer Declares First-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2018_dividend,Investments
630,2017-12-12,U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months,https://www.pfizer.com//news/press-release/press-release-detail/u_s_food_and_drug_administration_extends_action_date_for_xeljanz_tofacitinib_supplemental_new_drug_application_in_ulcerative_colitis_by_three_months,Medicines
631,2017-11-21,Ground-breaking €34 million project to develop better test for liver disease,https://www.pfizer.com//news/press-release/press-release-detail/ground-breaking-eu34-million-project-develop-better-test,Partnerships
